It is very uncertain whether postoperative MMC‐EMDA induction changes time to recurrence compared with postoperative BCG induction therapy (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with postoperative BCG induction therapy (very low certainty).
The review found no eligible studies for this question.
Postoperative MMC‐EMDA induction may leads to lower time to recurrence compared with MMC‐PD induction therapy (low certainty).
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with MMC‐PD induction therapy (very low certainty).
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with single‐dose, postoperative MMC‐PD (moderate certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with single‐dose, postoperative MMC‐PD (very low certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with single‐dose, postoperative MMC‐PD (low certainty).
The review found no eligible studies for this question.
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with TURBT alone (moderate certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with TURBT alone (very low certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with TURBT alone (moderate certainty).
The review found no eligible studies for this question.